Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RARE Stock Chart & Stats
$20.45
-$0.60(-1.35%)
At close: 4:00 PM EST
$20.45
-$0.60(-1.35%)
Day’s Range― - ―
52-Week Range$18.41 - $45.00
Previous CloseN/A
Volume75.38K
Average Volume (3M)2.65M
Market Cap
$1.95B
Enterprise Value$1.97B
Total Cash (Recent Filing)$737.00M
Total Debt (Recent Filing)$12.00M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 30, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding96,477,570
10 Day Avg. Volume2,572,368
30 Day Avg. Volume2,650,247
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)140.34
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.93
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda-4.04
Forecast
1Y Price Target
$53.35Price Target Upside160.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsPositive pivotal Phase 3 results for GTX-102 in Angelman syndrome could act as a major catalyst by validating the gene therapy approach and unlocking significant clinical value.
Cost Reduction And ProfitabilityStrategic restructuring with planned reductions in research and selling expenses is intended to materially lower operating costs and support a clear path toward GAAP profitability.
Undervalued Development PipelineCurrent share levels appear to price mainly the commercial franchise, creating potential upside if multiple development-stage programs advance successfully and capture market attention.
Bears Say
Commercial Guidance WeaknessSofter guidance for Crysvita tied to uneven ordering patterns in Latin America may reduce near-term revenue visibility and weigh on investor sentiment about growth durability.
Regulatory Resubmission UncertaintyAn incomplete response from regulators to a biologics resubmission that requests additional manufacturing documentation creates uncertainty about approval timelines and could delay commercial launch plans.
Voucher Market RiskUncertainty around the pediatric rare disease priority review voucher market and potential program extensions could lower expected proceeds from voucher sales and reduce a potential nonoperating revenue source.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $18.41 and its highest was $45.00 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $1.95B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Apr 30, 2026 which is in 70 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Feb 12, 2026. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$1.093 by -$0.197.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.39.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 96,477,570 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.29 in its last earnings report, missing expectations of -$1.093. Following the earnings report the stock price went down -12.681%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.35 (160.88% Upside)
$53.35 (160.88% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 30.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $184.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Bullish
Bullish news 64%
Bearish news 36%
Bearish news 36%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.84%
12-Months-Change
Fundamentals
Return on Equity
-656.54%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
RARE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear commercial momentum and promising late-stage clinical progress with meaningful near-term challenges. Highlights include 20% revenue growth in 2025, strong product-level growth (Crysvita +17%, Evkeeza +84%), an expanded global commercial footprint, multiple imminent clinical/regulatory catalysts (DTX401 rolling BLA with expected Q3 2026 PDUFA, GTX-102 Phase III readout H2 2026), and a restructuring plan targeting profitability in 2027 (notably R&D and SG&A reductions). Offsetting these positives are a significant FY2025 net loss ($575M), a CRL for UX111 that requires a resubmission and delays potential approval, high combined R&D/SG&A spend (~$1.1B), a 10% workforce reduction, and regulatory uncertainty around biomarker acceptance and reliance on PRVs and approvals to reach profitability. Overall, the call conveys progress and a credible path forward but with substantial execution and regulatory risks that temper near-term optimism.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$53.35
▲(160.88% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.99% Insiders
29.05% Mutual Funds
4.23% Other Institutional Investors
47.80% Public Companies and Individual Investors